A Case Report of Gynecomastia Due to Rosuvastatin
Korean Journal of Family Practice
;
(6): 471-474, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-787490
ABSTRACT
Gynecomastia is a common benign disease characterized by the progressive enlargement of the glandular tissue of the male breast due to an imbalance between the levels of estrogen and androgen in the blood. The etiology may vary and may be physiological, pharmacological, pathological, or even idiopathic. Among men, drug-induced gynecomastia may account for 10% to 20% of cases. The literature contains six case reports of rosuvastatin-induced gynecomastia. Withdrawal of statin or switching to a less potent statin can lead to symptom improvement and avoidance of unnecessary tests and patient anxiety. A 62-year-old male patient developed unilateral gynecomastia after 13 months of rosuvastatin therapy. After switching to a different statin (pravastatin), his symptoms improved within 2 months. Thus, clinicians should be aware of the possibility of occurrence of gynecomastia when statins are prescribed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Ansiedad
/
Mama
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
/
Estrógenos
/
Rosuvastatina Cálcica
/
Ginecomastia
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Korean Journal of Family Practice
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS